Polymer-Drug Conjugate Therapeutics: Advances, Insights, and Prospects

By Iriny Ekladious, Y. Colson, M. Grinstaff. Nature reviews. Drug discovery, 2018

686 citations recorded by the source corpus.

Polymer–drug conjugates have long been a mainstay of the drug delivery field, with several conjugates successfully translated into clinical practice. The conjugation of therapeutic agents to polymeric carriers, such as polyethylene glycol, offers several advantages, including improved drug solubilization, prolonged circulation, reduced immunogenicity, controlled release and enhanced safety. In this Review, we discuss the rational design, physicochemical characteristics and recent advances in the development of different classes of polymer–drug conjugates, including polymer–protein and polymer–small-molecule drug conjugates, dendrimers, polymer nanoparticles and multifunctional systems. Current obstacles hampering the clinical translation of polymer–drug conjugate therapeutics and future prospects are also presented. The conjugation of therapeutic agents to polymer carriers, such as polyethylene glycol (PEG), can control drug delivery, enhance solubilization, increase efficacy and improve pharmacokinetics. Here, Grinstaff, Colson and Ekladious discuss recent advances in the preclinical and clinical development of different classes of polymer–drug conjugates and highlight current challenges and future directions.

Subfields: Biomaterials, Biomedical Engineering, Polymers and Plastics

View Paper: https://www.semanticscholar.org/paper/6487070e4f40f1c0fb5fe695c7eb2e5207b9450f